Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LEGN Legend Biotech Corp
- Stocks
- Healthcare
- NASDAQ: LEGN
Price (delayed)
$27.78
Market cap
$5.11B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.2
Enterprise value
$4.47B
legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated
Highlights
The gross profit has soared by 166% YoY and by 22% from the previous quarter
The revenue has surged by 112% year-on-year and by 16% since the previous quarter
The EPS has surged by 53% year-on-year but it has declined by 25% since the previous quarter
The company's net income has surged by 53% YoY but it fell by 23% QoQ
The equity is down by 13% YoY and by 2.2% from the previous quarter
Legend Biotech's debt has increased by 8% YoY and by 3.5% QoQ
Key stats
What are the main financial stats of LEGN
Market
Valuations
Earnings
Shares outstanding
184.03M
Market cap
$5.11B
Enterprise value
$4.47B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.01
Price to sales (P/S)
7.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.14
Revenue
$728.3M
Gross profit
$477.12M
Operating income
-$133.21M
Net income
-$218.15M
EBIT
-$176.27M
EBITDA
-$153.44M
Free cash flow
-$285.65M
Per share
Balance sheet
Liquidity
EPS
-$1.2
EPS diluted
-$1.2
Free cash flow per share
-$1.56
Book value per share
$5.54
Revenue per share
$3.97
TBVPS
$8.79
Total assets
$1.62B
Total liabilities
$597.9M
Debt
$362.81M
Equity
$1.02B
Working capital
$984.42M
Debt to equity
0.36
Current ratio
5.2
Quick ratio
4.29
Net debt/EBITDA
4.19
Margins
Efficiency
Dividend
EBITDA margin
-21.1%
Gross margin
65.5%
Net margin
-30%
Operating margin
-18.3%
Return on assets
-12.8%
Return on equity
-20.1%
Return on invested capital
-27.7%
Return on capital employed
-12.8%
Return on sales
-24.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEGN stock price
How has the Legend Biotech stock price performed over time
Intraday
0.33%
1 week
-12.59%
1 month
-16.98%
1 year
-40.09%
YTD
-14.63%
QTD
-18.13%
Financial performance
How have Legend Biotech's revenue and profit performed over time
Revenue
$728.3M
Gross profit
$477.12M
Operating income
-$133.21M
Net income
-$218.15M
Gross margin
65.5%
Net margin
-30%
The gross profit has soared by 166% YoY and by 22% from the previous quarter
The revenue has surged by 112% year-on-year and by 16% since the previous quarter
The operating margin has soared by 83% YoY and by 16% QoQ
Legend Biotech's net margin has surged by 78% YoY but it has decreased by 6% QoQ
Price vs fundamentals
How does LEGN's price correlate with its fundamentals
Growth
What is Legend Biotech's growth rate over time
Valuation
What is Legend Biotech stock price valuation
P/E
N/A
P/B
5.01
P/S
7.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.14
The EPS has surged by 53% year-on-year but it has declined by 25% since the previous quarter
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 11.8 and 25% less than its last 4 quarters average of 6.7
The equity is down by 13% YoY and by 2.2% from the previous quarter
The revenue has surged by 112% year-on-year and by 16% since the previous quarter
The P/S is 87% less than the 5-year quarterly average of 55.2 and 47% less than the last 4 quarters average of 13.2
Efficiency
How efficient is Legend Biotech business performance
The return on sales has surged by 81% year-on-year but it has declined by 11% since the previous quarter
LEGN's return on invested capital has surged by 56% year-on-year but it is down by 27% since the previous quarter
LEGN's return on assets is up by 49% year-on-year but it is down by 27% since the previous quarter
The company's return on equity rose by 44% YoY but it fell by 27% QoQ
Dividends
What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEGN.
Financial health
How did Legend Biotech financials performed over time
Legend Biotech's total assets is 170% more than its total liabilities
The quick ratio has contracted by 18% YoY but it has grown by 5% from the previous quarter
Legend Biotech's current ratio has increased by 13% QoQ but it has decreased by 8% YoY
Legend Biotech's debt is 64% lower than its equity
The debt to equity has grown by 24% YoY and by 6% from the previous quarter
The equity is down by 13% YoY and by 2.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.